Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Share-based Compensation (2020 - 2025)

Cytek Biosciences' Share-based Compensation history spans 6 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 21.08% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $24.6 million, down 8.43%, while the annual FY2025 figure was $24.6 million, 8.43% down from the prior year.
  • Share-based Compensation reached $5.5 million in Q4 2025 per CTKB's latest filing, down from $5.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.2 million in Q2 2024 to a low of $456000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.9 million, with a median of $5.6 million recorded in 2025.
  • Peak YoY movement for Share-based Compensation: soared 1848.41% in 2021, then dropped 21.08% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.0 million in 2021, then soared by 48.44% to $4.5 million in 2022, then grew by 26.97% to $5.7 million in 2023, then increased by 23.53% to $7.0 million in 2024, then decreased by 21.08% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Share-based Compensation are $5.5 million (Q4 2025), $5.6 million (Q3 2025), and $6.8 million (Q2 2025).